Types of vaccines for COVID-19

Types of vaccines for COVID-19Peter A. Jensen2023-02-24T16:55:03+00:00

FOR EDUCATIONAL AND KNOWLEDGE SHARING PURPOSES ONLY.

SOURCE. British Society for Immunology

On this page, you will find infographics to explain how different types of vaccines work, including the Pfizer/BioNTech vaccine, the Moderna vaccine and the Oxford/AstraZeneca vaccine. Scroll down to discover more, click the download link to print the graphic or share on social media tagging @britsocimm to help strengthen public understanding.

As the UK COVID-19 vaccine approval and roll out continues to evolve, these infographics will be updated. They are accurate as of August 2022.

Vaccines train your immune system using a harmless form of the virus, SARS-CoV-2, which causes COVID-19. Vaccines stimulate an immune response without causing illness. Each type of vaccine for COVID-19 works differently to introduce antigens, which are unique features of the SARS-CoV-2 virus, to your body. The antigen triggers a specific immune response and this response builds immune memory, so your body can fight off SARS-CoV-2 in future.

Viral vector vaccines for COVID-19

The University of Oxford/AstraZeneca vaccine uses this technology to protect against COVID-19. This type of vaccine uses an unrelated harmless virus (the viral vector) to deliver SARS-CoV-2 genetic material. When administered, our cells use the genetic material to produce a specific viral protein, which is recognised by our immune system and triggers a response. This response builds immune memory, so your body can fight off the virus in future.

Viral vector vaccines for COVID-19

Download this infographic (PDF) (117 KB)

Download

Download this infographic (PNG for use on social media)

Genetic vaccines for COVID-19

The Moderna and Pfizer/BioNTech COVID-19 vaccines use this type of technology to train the immune system. The vaccines contains a segment of genetic material of the SARS-CoV-2 virus, which causes COVID-19. The genetic material, RNA in the case of Moderna and Pfizer/BioNTech vaccine, codes for a specific viral protein. When administered, your cells use the genetic material from the vaccines to make the protein, which is recognised by your immune system and triggers a specific response. This response builds immune memory, so your body can fight off SARS-CoV-2 in future.

Genetic vaccines for COVID-19

Download this infographic (PDF) (115 KB)

Download

Download this infographic (PNG for use on social media)

Inactivated vaccines for COVID-19

This type of vaccine contains the killed SARS-CoV-2 virus, which is recognised by the immune system to trigger a response without causing COVID-19 illness. This response builds immune memory, so your body can fight off SARS-CoV-2 in future.

Inactivated vaccines for COVID-19

Download this infographic (PDF) (128 KB)

Download

Download this infographic (PNG for use on social media)

Attenuated vaccines for COVID-19

This type of vaccine contains the weakened SARS-CoV-2 virus, which is recognised by the immune system to trigger a response without causing COVID-19 illness. This response builds immune memory, so your body can fight off SARS-CoV-2 in future.

BSI Attenuated COVID19 Vaccine

Download this infographic (PDF) (81 KB)

Download

Download this infographic (PNG for use on social media)

Protein vaccines for COVID-19

This type of vaccine contains proteins from the SARS-CoV-2 virus, which are recognised by the immune system to trigger a response. This response builds immune memory, so your body can fight off SARS-CoV-2 in future.

Protein vaccines for COVID-19

Download this infographic (PDF) (124 KB)

Download

Download this infographic (PNG for use on social media)

If you are interested in translating these resources into another language, please email bsi@immunology.org. Please do not translate these resources without our permission

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.